TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04895956

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intra-sheath injection
Description: Ultrasound guided corticosteroid injection composed of 1ml of 1% lidocaine and 1ml (20mg) of dexamethasone. Injection will be administered directly into the abductor pollicis longus/ extensor pollicis brevis sheath.
Study: NCT05921032

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise intervention
Description: 8 weeks of exercise with two session in a week

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise intervention
Description: 8 weeks of exercise with two session in a week
Study: NCT04922268

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Internal focus of attention feedback
Description: Participants will complete 12 sessions over a 3-week period of functional movement retraining while receiving mirror feedback. Participants will be instructed to perform each functional task in a manner that keeps their knee in line with their toes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: External focus of attention feedback
Description: Participants will complete 12 sessions over a 3-week period of functional movement retraining while receiving visual feedback via laser. Participants will be instructed to perform each functional task in a manner that does causes the laser to move up and down but not side-to-side.
Study: NCT04895956

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extra-sheath injection
Description: Ultrasound guided corticosteroid injection composed of 1ml of 1% lidocaine and 1ml (20mg) of dexamethasone. Injection will be administered surrounding the abductor pollicis longus/ extensor pollicis brevis sheath.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: To ensure accuracy of fluid deposition into the tendon sheath in the intra-sheath injection arm and outside of the tendon sheath in the extra-sheath injection arm, all injections will be performed under ultrasound guidance. The ultrasound machine used will be a portable ultrasound machine located at the UC Davis orthopaedic clinic in Sacramento

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: To ensure accuracy of fluid deposition into the tendon sheath in the intra-sheath injection arm and outside of the tendon sheath in the extra-sheath injection arm, all injections will be performed under ultrasound guidance. The ultrasound machine used will be a portable ultrasound machine located at the UC Davis orthopaedic clinic in Sacramento
Study: NCT06400121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apimostinel Infusion, Intravenous
Description: Single injection of Apimostinel (10mg)

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Apimostinel Infusion, Intravenous
Description: Single injection of Apimostinel (10mg)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: 8 sessions of digital active training

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Training
Description: 8 sessions of digital active training

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Training
Description: 8 sessions of digital sham training

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic Solution, Intravenous
Description: Single injection of placebo
Study: NCT06343792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLS-0071
Description: RLS-0071 will be administered for 7 or 14 days according to the assigned dose group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLS-0071
Description: RLS-0071 will be administered for 7 or 14 days according to the assigned dose group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLS-0071
Description: RLS-0071 will be administered for 7 or 14 days according to the assigned dose group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLS-0071
Description: RLS-0071 will be administered for 7 or 14 days according to the assigned dose group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLS-0071
Description: RLS-0071 will be administered for 7 or 14 days according to the assigned dose group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLS-0071
Description: RLS-0071 will be administered for 7 or 14 days according to the assigned dose group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLS-0071
Description: RLS-0071 will be administered for 7 or 14 days according to the assigned dose group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLS-0071
Description: RLS-0071 will be administered for 7 or 14 days according to the assigned dose group.
Study: NCT05702047

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nose-only breathing
Description: Participants will breathe only through their nose (mouth closed) during rest and submaximal exercise.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mouth-only breathing
Description: Participants will breathe only through their mouth (nose clips prevent nose breathing) during rest and submaximal exercise.
Study: NCT05835973

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep activity
Description: Actinography : Patient will wear actinometers on the wrist for 1 year continuously. In the study, MotionWatch 8 actimeters will be used, a class 1 medical device with CE mark (EN ISO 13485:2016 standard).~Ancillary study :~DREEM 3 headband : a subgroup of patients will wear the headband during 2 nights every 3 months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: The PSQI, EPWORTH, FACIT-F, ISI, and ICSD-3 questionnaires will be completed by patients every 3 months during their follow-up consultation according to the usual management.~The questionnaire by Horne and Ostberg will be completed by the patients only during the inclusion visit.
Study: NCT05422794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BET Bromodomain Inhibitor ZEN-3694
Description: Given PO
Study: NCT06373848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Receive 30 mg of Coq10
Description: A total of 120 individuals diagnosed with chronic periodontitis were selected for this study. These participants were randomly assigned to two different groups. The purpose of the study was to measure the periodontal parameters of the two molars adjacent to the mandible using a periodontal probe. All of the patients received scaling and root planing (SRP) as part of their treatment. However, the treatment groups differed in terms of the supplements they received. Group A was given a daily dose of Coq10 at 30 mg, while Group B received a daily dose of Vitamin E at 400 mg; Furthermore, group C did not receive any supplements. The periodontal examination involved a total of 300 teeth across the three groups. In addition to this, 2 ml of unstimulated saliva was collected from each patient both before and after 2 months. The purpose of collecting the saliva samples was to evaluate the total antioxidant capacity and determine if there were any changes over time.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Receive 30 mg of Coq10
Description: A total of 120 individuals diagnosed with chronic periodontitis were selected for this study. These participants were randomly assigned to two different groups. The purpose of the study was to measure the periodontal parameters of the two molars adjacent to the mandible using a periodontal probe. All of the patients received scaling and root planing (SRP) as part of their treatment. However, the treatment groups differed in terms of the supplements they received. Group A was given a daily dose of Coq10 at 30 mg, while Group B received a daily dose of Vitamin E at 400 mg; Furthermore, group C did not receive any supplements. The periodontal examination involved a total of 300 teeth across the three groups. In addition to this, 2 ml of unstimulated saliva was collected from each patient both before and after 2 months. The purpose of collecting the saliva samples was to evaluate the total antioxidant capacity and determine if there were any changes over time.
Study: NCT05422794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BET Bromodomain Inhibitor ZEN-3694
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study: NCT06418984

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: auxiliary
Description: the interventions are related to the adjuncts associated with clear aligners to improve the predictability and accuracy of tooth movement

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: auxiliary
Description: the interventions are related to the adjuncts associated with clear aligners to improve the predictability and accuracy of tooth movement

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: auxiliary
Description: the interventions are related to the adjuncts associated with clear aligners to improve the predictability and accuracy of tooth movement
Study: NCT04914273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhalation Spray
Description: 400 mcg salbutamol administered per metered dose inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhalation Spray
Description: 400 mcg salbutamol administered per metered dose inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tablet
Description: 8 mg salbutamol administered per tablet for ingestion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tablet
Description: 8 mg salbutamol administered per tablet for ingestion
Study: NCT05071027

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endovascular Neurosurgery
Description: Custom Dual Antiplatelet Therapy reminders for patients receiving endovascular treatment of cerebral unruptured aneurysms. The app utilized to generate reminders is available on the Apple app store.
Study: NCT05422794

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study: NCT06039267

Intervention type: OTHER
Intervention: Gut Microbiome Testing
Description: Stool microbiome testing using shotgun metagenomic sequencing
Study: NCT05422794

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT05550727

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PorchLight
Description: The PorchLight Project intervention consists of three components: 1) CARES® Dementia Care Specialist online training modules; 2) a PorchLight Project training course; and 3) monthly check-in sessions.
Study: NCT05611801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: marstacimab
Description: marstacimab
Study: NCT05843565

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cobalt video laryngoscope blade
Description: Non-standard hyperangulated Cobalt video laryngoscope blade

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Cobalt video laryngoscope blade
Description: Non-standard hyperangulated Cobalt video laryngoscope blade

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Miller video laryngoscope blade
Description: Standard Miller video laryngoscope blade

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Miller video laryngoscope blade
Description: Standard Miller video laryngoscope blade
Study: NCT06433193

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PAK HD Sorbent Therapy
Description: Study Period 1:~Subjects will receive their normal prescribed 4h CHD treatments Monday or Tuesday. On Wednesday or Thursday, one 4h CHD therapy will be performed at a dialysate flow rate (QD) of 300mL/min, identical to the dialysate flow rate of the PAK HD sorbent therapy. Blood and dialysate samples will be collected during treatment and sent for analysis, for comparison with PAK HD sorbent treatment.~Study Period 2:~Subjects will again receive their normal prescribed 4h CHD treatments Monday or Tuesday. On Wednesday or Thursday, a 2h PAK HD +/- 2h CHD therapy will be performed. Blood and dialysate samples will again be collected during treatment and sent for analysis, for comparison with the CHD therapy of the first period. After completion of study period 2 (PAK HD +/- CHD), subjects will be observed for a minimum duration of 1 h in the hospital after which they may go home if the post-dialysis period was uneventful.
Study: NCT05085392

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma-Informed Yoga
Description: 6 weeks of twice weekly trauma-informed yoga for 45 minutes per session
Study: NCT06297408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relma-cel
Description: CD19-targeted Chimeric AntigenReceptor (CAR) T Cells
Study: NCT05524948

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Dentifrice
Description: Dentifrice containing 0.454% stannous fluoride with 0.3% zinc chloride.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reference Dentifrice
Description: Standard fluoride dentifrice containing 0.243% sodium fluoride.
Study: NCT06642857

Intervention type: OTHER
Intervention: Peripheral blood, tougue coating, saliva, and feces
Description: Peripheral blood, coating, saliva, and feces on the tongue and clinical data of patients with advanced gastric cancer patients who received chemotherapy combined with immunotherapy will be collected.
Study: NCT06639412

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Networking the indigenous parent-teacher association and agriculture development agents with the PHC unit to enhance NCD prevention & control services.
Description: The intervention will be networking the indigenous parent-teacher association and agriculture development agents with the PHC unit to enhance NCD prevention \& control services. In this major activity, the project team will establish the network by incorporating agricultural development agents and parents- teacher associations to the health post as foundational actors for educating the community on NCD prevention and control measures. We will implement tier system training to effectively create awareness on NCD and to enhance the NCD care-seeking behavior of the community.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: The community in the control group will get noncommunicable disease prevention and control measures given through the health care system.
Study: NCT05727163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 25mg via HAI (Pre-chemotherapy)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anisodamine
Description: 10 mg via HAI (Pre-chemotherapy)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m2 via HAI over 3 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 200 mg/m2 via HAI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 400 mg/m2 via HAI and 2.4g/m2 via HAI over 48 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 150 mg/m2 intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: 150 mg/m2 intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5 mg/kg intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 5 mg/kg intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: 85 mg/m2 intravenously over 3 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: 200 mg/m2 intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: 400 mg/m2 intravenously + 2400 mg/m2 continuous intravenous infusion over 46 hours
Study: NCT06116435

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prevent T2
Description: The PreventT2 curriculum is based on the original 2002 Diabetes Prevention Prevention (DPP) trial and follow-up studies. It promotes modest weight loss (5-7%) and increased physical activity through a lifestyle change program and also reflects new literature on self-efficacy, physical activity, and diet. There are 16 modules that will be delivered over 6 months. Participants will receive a calorie goal and be asked to count calories in order to reduce their caloric intake.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prevent T2
Description: The PreventT2 curriculum is based on the original 2002 Diabetes Prevention Prevention (DPP) trial and follow-up studies. It promotes modest weight loss (5-7%) and increased physical activity through a lifestyle change program and also reflects new literature on self-efficacy, physical activity, and diet. There are 16 modules that will be delivered over 6 months. Participants will receive a calorie goal and be asked to count calories in order to reduce their caloric intake.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prevent T2
Description: The PreventT2 curriculum is based on the original 2002 Diabetes Prevention Prevention (DPP) trial and follow-up studies. It promotes modest weight loss (5-7%) and increased physical activity through a lifestyle change program and also reflects new literature on self-efficacy, physical activity, and diet. There are 16 modules that will be delivered over 6 months. Participants will receive a calorie goal and be asked to count calories in order to reduce their caloric intake.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prevent T2
Description: The PreventT2 curriculum is based on the original 2002 Diabetes Prevention Prevention (DPP) trial and follow-up studies. It promotes modest weight loss (5-7%) and increased physical activity through a lifestyle change program and also reflects new literature on self-efficacy, physical activity, and diet. There are 16 modules that will be delivered over 6 months. Participants will receive a calorie goal and be asked to count calories in order to reduce their caloric intake.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prevent T2
Description: The PreventT2 curriculum is based on the original 2002 Diabetes Prevention Prevention (DPP) trial and follow-up studies. It promotes modest weight loss (5-7%) and increased physical activity through a lifestyle change program and also reflects new literature on self-efficacy, physical activity, and diet. There are 16 modules that will be delivered over 6 months. Participants will receive a calorie goal and be asked to count calories in order to reduce their caloric intake.
Study: NCT06070350

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Low Titer Group O Whole Blood (LTOWB)
Description: LTOWB is whole blood from group O donors with low titer (\<200) anti-A and anti-B antibodies. Up to 8 units of LTOWB will be allowed unless local clinical practice allows for a higher maximum dose.
Study: NCT06070350

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Low Titer Group O Whole Blood (LTOWB)
Description: LTOWB is whole blood from group O donors with low titer (\<200) anti-A and anti-B antibodies. Up to 8 units of LTOWB will be allowed unless local clinical practice allows for a higher maximum dose.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo will be provided to the research pharmacy at each of the clinical sites

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo will be provided to the research pharmacy at each of the clinical sites

Intervention type: DRUG
Group type: OTHER
Intervention: Tranexamic Acid (TXA)
Description: TXA is a synthetic lysine analog that competitively inhibit activation of plasminogen, thereby decreasing the conversion of plasminogen to plasmin, preventing degradation of fibrin's matrix structure. Dose is 25mg/kg IV or IO (maximum 2 grams).
Study: NCT05863221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZYNRELEF 200Mg-6Mg Extended-Release Solution
Description: ZYNRELEF® is an extended-release, fixed-ratio combination product that contains bupivacaine (a local anesthetic as the free base) and low-dose meloxicam (an NSAID) incorporated in a bioerodible polymer (termed Biochronomer®).
Study: NCT06070350

Intervention type: DRUG
Group type: OTHER
Intervention: Tranexamic Acid (TXA)
Description: TXA is a synthetic lysine analog that competitively inhibit activation of plasminogen, thereby decreasing the conversion of plasminogen to plasmin, preventing degradation of fibrin's matrix structure. Dose is 25mg/kg IV or IO (maximum 2 grams).

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Component Therapy (CT)
Description: Component Therapy (CT) will be RBCs, plasma and platelet units in a 1:1:1 unit ratio. This will be given with Placebo

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Component Therapy (CT)
Description: Component Therapy (CT) will be RBCs, plasma and platelet units in a 1:1:1 unit ratio. This will be given with Placebo
Study: NCT06563752

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Participants will use 3D glasses to view VR educational information
Description: Participants will use 3D glasses to view VR educational information, which includes:~1. Understanding of psychiatric symptoms, including symptoms, disease course, treatment, and prognosis.~2. Knowledge about medications, their relationship with symptom stabilization, and handling of side effects.~3. Schizophrenia as a chronic illness, with analogies to other chronic diseases.~4. Signs of disease relapse.~5. How to manage ongoing psychiatric symptoms of schizophrenia, including delusions, hallucinations, paranoia, and negative symptoms.~6. Strategies for interacting and communicating with patients.~7. Stress management and adjustment, as well as suicide prevention.~8. Available resources.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: routine care
Description: Before discharge, provide routine discharge preparation instructions and offer a disease education booklet with relevant health information. Follow up with two phone calls after discharge, on the 7th and 30th days.